BRAF-mutated metastatic metastatic melanoma: maintenance of the long-term efficacy of the anti-BRAF/anti-MEK combination
Benefits of anti-BRAF/anti-MEK combination on overall survival in patients with BRAFV600 mutated metastatic melanoma are maintained after 24 additional months ...
Read more